A Review on Recombinant Technology for the Treatment of Liver Diseases

The complicated etiologies and restricted treatment options of liver illnesses, which range from metabolic and autoimmune disorders to viral hepatitis and jaundice, pose serious threats to world health. Recombinant DNA technology has become a game-changer in the identification, management, and avoidance of many diseases. This overview describes the pathophysiology of major liver ailments, the anatomical and physiological relevance of the liver, and how recombinant technology is used to treat them. Therapeutic proteins like interferons and clotting factors, as well as recombinant vaccinations like those for hepatitis B, have been made possible by developments in molecular biology. Additionally, in vivo and ex vivo gene therapy has demonstrated encouraging outcomes in treating hereditary liver diseases such as Wilson disease and Crigler-Najjar syndrome.Early and precise detection of liver illnesses, including autoimmune and metabolic variations, is also made possible by the combination of recombinant DNA technology with molecular diagnostics. The clinical potential of recombinant therapies is still being expanded by continuous advancements, despite obstacles including immune responses and vector delivery constraints. This review highlights how recombinant technology is essential to changing hepatology by facilitating more efficient, specialized, and individualizedtreatment approaches.